Episode Details

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:

• Epidemiology and burden of nosocomial bacterial pneumonia
• Patient-specific risk factors for MDR pathogens
• Improving outcomes with the use of antibiograms
• Recommended empiric therapy for clinically suspected VABP
• Antimicrobial resistance in HABP/VABP
• Algorithms for gram-negative organism antibiotic-susceptibility testing
• Using rapid diagnostic tests for HABP/VABP
• New antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:
  • ASPECT-NP: ceftolozane/tazobactam vs meropenem
  • REPROVE: ceftazidime/avibactam vs meropenem
  • RESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenem
  • RESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactam
  • APEKS-NP: cefiderocol vs meropenem
  • CREDIBLE-CR: cefiderocol vs best available therapy

Program Director:

Keith S. Kaye, MD, MPH
Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson 
Medical School
New Brunswick, New Jersey

Faculty:

Lilian Abbo, MD, FIDSA
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Jason M. Pogue, PharmD
Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.

Follow along with a downloadable slideset at:
https://bit.ly/3CEop6h

Link to full program
 https://bit.ly/3i781lf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.